Alcohol-associated hepatitis (AH) is a critical global health issue characterized by acute liver inflammation and an elevated risk of mortality in its severe form (sAH). While the condition has been studied extensively, effective treatments remain scarce, with liver transplantation often being the only viable option for patients with advanced disease.
In their recent editorial, Dr. Bin Gao and his colleagues at the National Institutes of Health provide an in-depth analysis of IL-8+ neutrophils, which are implicated as central drivers of the inflammation associated with sAH. The editorial consolidates findings from multiple studies, shedding light on the molecular mechanisms that underpin the condition and identifying IL-8 signaling as a potential therapeutic pathway.
Neutrophil infiltration, a hallmark of sAH, is driven by elevated levels of IL-8, a chemokine crucial in recruiting and activating immune cells. Unlike other liver diseases, sAH features an abundance of IL-8+ neutrophils within the liver, amplifying a vicious cycle of inflammation and tissue damage. These unique characteristics make IL-8+ neutrophils an attractive focus for therapeutic interventions.
"By targeting IL-8+ neutrophils, we can develop treatments that selectively reduce inflammation in sAH without affecting other liver conditions," said Dr. Gao.
The editorial highlights several strategies for targeting IL-8 signaling. These include therapeutic antibodies like ABX-IL-8 and HuMax-IL-8 (BMS-986253), CXCR1/CXCR2 inhibitors, and p38 MAPK inhibitors.
The authors emphasize the importance of addressing potential challenges, including the risk of infections when using anti-IL-8 therapies. They propose combination approaches, such as pairing anti-IL-8 agents with antibiotics or IL-22, a cytokine with hepatoprotective effects, to enhance safety and efficacy.
The editorial also underscores the broader relevance of IL-8+ neutrophils beyond sAH. These cells have been implicated in other inflammatory and neoplastic conditions, such as severe COVID-19 and hepatocellular carcinoma, indicating their potential as universal therapeutic targets.
While the editorial does not present new experimental data, it synthesizes existing findings to propose a clear direction for future research. By focusing on IL-8+ neutrophils, the authors aim to catalyze the development of targeted therapies that could transform the treatment landscape for sAH and related conditions.
"Our work highlights the critical role of IL-8+ neutrophils in sAH and underscores the need for interdisciplinary collaboration to develop effective therapies," Dr. Gao stated.
As the field of hepatology advances, integrating insights from molecular biology, immunology, and pharmacology will be essential. This editorial is a valuable roadmap for researchers and clinicians seeking to address the unmet medical needs associated with sAH, improving patient outcomes worldwide.
See the article:
Guan Y, Feng D, Maccioni L, et al. New therapeutic target for alcohol-associated hepatitis (AH): AH-associated IL-8+ neutrophils. eGastroenterology 2024;2:e100166. doi:10.1136/egastro-2024-100166
About eGastroenterology
eGastroenterology is a new, open-access, and open peer-reviewed BMJ Journal, which focuses on basic, clinical, translational, and evidence-based medicine research in all areas of gastroenterology (including hepatology, pancreatology, esophagology, and gastrointestinal surgery). eGastroenterology is now indexed by PubMed Central, Scopus, CAS, DOAJ, Dimensions, OpenAlex, ROAD, and COPE, with more to come!
